Pleiotropic actions of the gastroenteroprotector rebamipide


DOI: https://dx.doi.org/10.18565/therapy.2020.4.142-151

Vorobyeva N.M., Tkacheva O.N.

N.I. Pirogov Russian national research medical university of the Ministry of Healthcare of Russia – SABU «Russian Gerontological Scientific and Clinical Center», Moscow
The review contains information concerning the pleiotropic effects of gastroenteroprotector rebamipide, such as anti-inflammatory, antioxidant, pro-angiogenic, carcinogenic, also effect of elimination of increased permeability of the intestinal wall, restoration of the integrity of intestinal protective barrier, protection and restoration of mucous membranes in various organs. In our opinion, the ability of rebamipide to eliminate increased intestinal permeability and restore the integrity of the intestinal barrier is the most important of the pleiotropic effects, since it opens up the possibilities for its use as a basic remedy of pathogenetic therapy for many chronic diseases. Anyway, it requires further clinical studies in this direction. In coronavirus infection pandemic conditions, the protective effect of rebamipide on the mucous membranes, including the respiratory tract and nasopharynx membranes, allows to prescribe the medicine for patients from the risk group to protect epithelial cells of the respiratory and gastrointestinal tracts from the virus.
Keywords: pleiotropic effect, rebamipide, gastroenteroprotector, increased permeability of the intestinal wall
Read entire article

Literature


  1. Оганов Р.Г., Симаненков В.И., Бакулин И.Г. с соавт. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019; 18(1): 5–66. [Oganov R.G., Simanenkov V.I., Bakulin I.G. et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Kardiovasculyarnaya terapiya i profilaktika. 2019; 18(1): 5–66 (In Russ.)]. doi: https://doi.org/10.15829/1728-8800-2019-1-5-66.

  2. Tarnawski A.S., Chai J., Pai R., Chiou S.K. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004; 49(2): 202–09. doi: 10.1023/b:ddas.0000017439.60943.5c.

  3. Choe J.Y., Park K.Y., Lee S.J. et al. Rebamipide inhibits tumor necrosis factor-α-induced interleukin-8 expression by suppressing the NF-κB signal pathway in human umbilical vein endothelial cells. Inflamm Res. 2010; 59(12): 1019–26. doi: 10.1007/s00011-010-0221-5.

  4. Naito Y., Yoshikawa T., Tanigawa T. et al. Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic Biol Med. 1995; 18(1): 117–23. doi: 10.1016/0891-5849(94)00110-6.

  5. Lai Y., Zhong W., Yu T. et al. Rebamipide Promotes the regeneration of aspirin-induced small-intestine mucosal injury through accumulation of β-Catenin. PLoS One. 2015; 10(7): e0132031. doi: 10.1371/journal.pone.0132031.

  6. Jang H., Park S., Lee J. et al. Rebamipide alleviates radiation-induced colitis through improvement of goblet cell differentiation in mice. J Gastroenterol Hepatol. 2018; 33(4): 878–86. doi: 10.1111/jgh.14021.

  7. Shim S., Jang H.S., Myung H.W. et al. Rebamipide ameliorates radiationinduced intestinal injury in a mouse model. Toxicol Appl Pharmacol. 2017; 329: 40–47. doi: 10.1016/j.taap.2017.05.012.

  8. Воробьева Н.М., Ткачева О.Н. Повышенная проницаемость кишечной стенки и ее роль в возникновении сердечно-сосудистых заболеваний. Фарматека, 2020; 27 (3): 122–128. [Vorobyeva N.M., Tkacheva O.N. Increased intestinal permeability and its role in the development of cardiovascular diseases. Farmateka. 2020; 27(3): 122–128. (In Russ.)]. doi: https: //dx.doi.org/10.18565/pharmateca.2020.3.00-00.

  9. Kimura K., Morita Y., Orita T. et al. Protection of human corneal epithelial cells from ФНО-α-induced disruption of barrier function by rebamipide. Invest Ophthalmol Vis Sci. 2013; 54 (4): 2572–2760. DOI: 10.1167/iovs.12-11294.

  10. Kase S., Shinohara T., Kase M., Ishida S. Effect of topical rebamipide on goblet cells in the lid wiper of human conjunctiva. Exp Ther Med, 2017; 13(6): 3516–22. doi: 10.3892/etm.2017.4390.

  11. Fukuda M., Shibata S., Shibata N. et al. Polyvinyl alcohol-iodine induced corneal epithelial injury in vivo and its protection by topical rebamipide treatment. PLoS One. 2018; 13(11): e0208198. doi: 10.1371/journal.pone.0208198.

  12. Haripriya A., Baam Z.R., Chang D.F. Endophthalmitis prophylaxis for cataract surgery. Asia Pac J Ophthalmol (Phila). 2017; 6(4): 324–29. doi: 10.22608/APO.2017200.

  13. Arimoto A., Kitagawa K., Mita N. et al. Effect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in Sjogren syndrome patients with or without punctal occlusions. Cornea. 2014; 33(8): 806–11. doi: 10.1097/ICO.0000000000000155.

  14. Fukuda M., Sasaki H. Quantitative evaluation of corneal epithelial injury caused by n-heptanol using a corneal resistance measuring device in vivo. Clin Ophthalmol. 2012; 6: 585–93. doi: 10.2147/OPTH.S30935.

  15. Chaitanya B., Pai K.M., Yathiraj P.H. et al. Rebamipide gargle in preventive management of chemo-radiotherapy induced oral mucositis. Oral Oncol. 2017; 72: 179–82. doi: 10.1016/j.oraloncology.2017.07.024.

  16. Akagi S., Fujiwara T., Nishida M. et al. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci. 2019; 5: 16. doi: 10.1186/s40780-019-0146-2.

  17. Lee S.Y., Kang E.J., Hur G.Y. et al. The inhibitory effects of rebamipide on cigarette smoke-induced airway mucin production. Respir Med. 2006; 100(3): 503–11. doi: 10.1016/j.rmed.2005.06.006.

  18. Gohil P., Thakkar H., Gohil U., Deshpande S. Preliminary studies on the effect of rebamipide against the trypsin and egg-albumin induced experimental model of asthma. Acta Pharm. 2011; 61(4): 427–33. doi: 10.2478/v10007-011-0033-3.

  19. Murakami I., Zhang R., Kubo M. et al. Rebamipide suppresses mite-induced asthmatic responses in NC/Nga mice. Am J Physiol Lung Cell Mol Physiol. 2015; 309(8): L872–78. doi: 10.1152/ajplung.00194.2015.

  20. Tanigawa T., Pai R., Arakawa T., Tarnawski A.S. Rebamipide inhibits gastric cancer cell growth. Dig Dis Sci. 2007; 52(1): 240–47. doi: 10.1007/s10620-006-9226-x.

  21. Tsukamoto H., Mizoshita T., Katano T. et al. Preventive effect of rebamipide on N-methyl-N’-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. Exp Toxicol Pathol. 2015; 67(3): 271–77. doi: 10.1016/j.etp.2015.01.003.

  22. Han X., Jiang K., Wang B. et al. Effect of Rebamipide on the premalignant progression of chronic gastritis: a randomized controlled study. Clin Drug Investig. 2015; 35(10): 665–73. doi: 10.1007/s40261-015-0329-z.

  23. Nishizawa T., Suzuki H., Nakagawa I. et al. Rebamipide-promoted restoration of gastric mucosal sonic hedgehog expression after early Helicobacter pylori eradication. Digestion. 2009; 79(4): 259–62. doi: 10.1159/000213241.

  24. Tanigawa T., Watanabe T., Ohkawa F. et al. Rebamipide, a mucoprotective drug, inhibits NSAIDs-induced gastric mucosal injury: possible involvement of the downregulation of 15-hydroxyprostaglandin dehydrogenase. J Clin Biochem Nutr. 2011; 48(2): 149–53. doi: 10.3164/jcbn.10-75.

  25. Pimentel-Nunes P., Libanio D., Marcos-Pinto R. et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019; 51(4): 365–88. doi: 10.1055/a-0859-1883.

  26. Маев И.Г., Казюлин А.Н. Новые возможности профилактики рака желудка. Терапевтический архив, 2017; 89(4): 101–09. [Maev I.G., Kazulin A.N. New opportunities for the prevention of gastric cancer. Terapevticheskiy arkhiv. 2017; 89(4): 101–09 (In Russ.)]. doi: 10.17116/terarkh2017894101-109.


About the Autors

Natalia M. Vorobyova, MD, head of the laboratory of cardiovascular aging of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia – SABU «Russian Gerontological Scientific and Clinical Center». Address: 129226, Moscow, 16 1st Leonova Str. Tel.: +7 (915) 192-22-78. Email: natalyavorobjeva@mail.ru
Olga N. Tkacheva, MD, professor, director of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia – SABU «Russian Gerontological Scientific and Clinical Center». Address: 129226, Moscow, 16 1st Leonova Str. Tel.: +7 (915) 192-22-78. E-mail: tkacheva@rgnkc.ru

Back to Content

Бионика Медиа